Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $4.19B
• Dividend Yield: N/A
• Average Volume (3M): 842.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: -49.51%
• EPS Growth: -44.09%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 71,497,600
• 10 Day Avg. Volume: 679,042
• 30 Day Avg. Volume: 842,737
• PEG Ratio: -0.74
• Price to Book (P/B): 3.61
• Price to Sales (P/S): 64.14
• P/FCF Ratio: -14.56
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 65.56
• Enterprise Value/Gross Profit: 68.76
• Enterprise Value/Ebitda: -10.58
• 1Y Price Target: $67.59
• Price Target Upside: 9.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 57 Neutral
• Price Target: $45.00 ▼(-27.36% Downside)

Kymera Therapeutics' overall stock score is driven by a strong earnings call that highlights strategic partnerships and a solid cash position, which partially offsets the financial challenges and valuation concerns. The technical analysis suggests positive momentum, but the company's unprofitability and lack of dividend yield weigh on the valuation score.

Positive Factors

Strategic Collaborations

These partnerships could unlock significant milestone payments and expand Kymera's reach in oncology and immuno-inflammatory treatments, enhancing its long-term growth prospects.

Financial Position

A strong cash position ensures Kymera can fund its operations and R&D activities, supporting sustained development and potential commercialization of its drug candidates.

Leadership Change

The appointment of an experienced legal executive can strengthen Kymera's governance and strategic planning, positively impacting its long-term operational efficiency and compliance.

Negative Factors

Revenue Decline

A decline in revenue growth can hinder the company's ability to fund R&D and operational activities, potentially impacting its long-term financial health and market competitiveness.

Operational Challenges

Persistent operational inefficiencies and negative profit margins can strain Kymera's resources, limiting its ability to invest in growth opportunities and achieve sustainable profitability.

Cash Flow Challenges

Negative operating cash flow suggests difficulties in generating sufficient cash from operations, which can affect Kymera's ability to finance its strategic initiatives and maintain financial stability.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics is a biotechnology company focused on developing innovative therapies that harness the power of targeted protein degradation to treat a variety of diseases, including cancer and autoimmune disorders. Leveraging its proprietary technology platform, Kymera aims to create a new class of drugs that can selectively eliminate disease-causing proteins, providing a novel approach to treatment in the pharmaceutical sector.

How the Company Makes Money

Kymera Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. The company may receive upfront payments, research funding, and milestone payments as its products progress through various stages of development. Additionally, Kymera could earn royalties on future sales of any approved therapies stemming from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its therapeutic candidates in clinical trials and the establishment of strategic alliances to enhance its research capabilities and market reach.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin, the company struggles with negative net income and operational inefficiencies. The balance sheet shows low leverage, but negative returns on equity highlight profitability issues. Cash flow improvements are modest, with ongoing challenges in generating positive operating cash flow.

Income Statement

Kymera Therapeutics has experienced declining revenue growth, with a significant drop of 24.07% in the TTM period. The company maintains a high gross profit margin of 95.34%, indicating efficient cost management. However, the net profit margin is deeply negative at -6.16%, reflecting substantial losses. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company has a low debt-to-equity ratio of 0.09, suggesting conservative leverage. However, the return on equity is negative at -31.60%, indicating that the company is not generating positive returns for shareholders. The equity ratio is relatively stable, showing a solid equity base compared to total assets.

Cash Flow

Kymera Therapeutics shows a slight improvement in free cash flow growth at 5.40% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.71M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	42.63M	47.07M	78.59M	43.85M	70.44M	-28.07M
EBITDA	-277.16M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-275.43M	-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet
Total Assets	1.13B	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	665.45M	488.74M	374.88M	559.49M	567.61M	458.73M
Total Debt	85.71M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	159.59M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	971.48M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-252.92M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-251.01M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	19.52M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	499.67M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 61.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Positive. The current price of 61.95 is above the 20-day moving average (MA) of 58.43, above the 50-day MA of 51.36, and above the 200-day MA of 40.68, indicating a bullish trend. The MACD of 2.30 indicates Positive momentum. The RSI at 62.96 is Neutral, neither overbought nor oversold. The STOCH value of 59.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AKRO	―	$4.31B	―	-31.14%	―	―	-11.39%
KYMR	―	$4.19B	―	-33.26%	―	-49.51%	-44.09%
PTGX	―	$4.66B	105.60	8.61%	―	-34.45%	-69.75%
APLS	―	$3.56B	―	-108.49%	―	20.02%	33.45%
CRNX	―	$3.96B	-10.23	-36.94%	―	―	-9.10%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLTX	―	$630.75M	―	-40.29%	―	―	-208.46%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Announces New Chief Legal Officer

On September 3, 2025, Kymera Therapeutics announced the retirement of Ellen Chiniara as Chief Legal Officer, with Brian R. Adams succeeding her. This leadership change is part of Kymera’s strategic efforts to advance its novel programs in the field of immunology, aiming to redefine treatment possibilities with groundbreaking oral medicines.

The most recent analyst rating on (KYMR) stock is a Hold with a $43.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress

Kymera Therapeutics’ recent earnings call painted a picture of optimism and strategic advancement. The company showcased significant progress in its clinical trials, highlighted by a robust pipeline and promising collaborations. Despite a strategic shift in the IRAK4 program, the overall sentiment remained positive, underscoring a strong financial position and a clear path forward.

Kymera Therapeutics Reports Q2 2025 Progress and Partnerships

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, leveraging targeted protein degradation technology to address previously inaccessible disease targets and pathways.